A Phase II Study of HS-10353 in Adult Participants With Major Depressive Disorder (MDD)

Publication date: Jul 10, 2023

This is a randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of continuous oral administration of HS-10353 in Chinese adults with depression. HS-10353 is a new generation of GABAA receptor isomeric modulator developed by our company, which can correct the dysfunction of GABAA receptor function and restore the balance between GABA receptor and NMDA receptor. Oral administration of HS-10353 at night for 14 days is expected to reduce clinical symptoms in patients with depression. As an oral preparation of allopregnenolone analogitics, it has good bioavailability, rapid onset and high safety, and has broad clinical application prospects, which is expected to better meet the treatment needs of clinical depression in China in the future.

Concepts Keywords
Carbamazepine Blood
Chinese Clinical
Depressive Current
Grapefruit Depressive


Type Source Name
drug DRUGBANK Tropicamide
drug DRUGBANK gamma-Aminobutyric acid
drug DRUGBANK Isoxaflutole
disease MESH Major Depressive Disorder
drug DRUGBANK Methionine
disease MESH Mental Disorders
disease MESH depressive disorder
disease MESH abnormalities
drug DRUGBANK Chorionic Gonadotropin (Human)
disease MESH schizophrenia
disease MESH psychosis
disease MESH dissociation
disease MESH anorexia
disease MESH bulimia nervosa
disease MESH personality disorders
disease MESH Suicide
disease MESH seizures
disease MESH febrile convulsions
disease MESH allergies
drug DRUGBANK Ethanol
disease MESH drug dependence
drug DRUGBANK Nicotine
drug DRUGBANK Caffeine
drug DRUGBANK Rifampicin
drug DRUGBANK Carbamazepine
drug DRUGBANK Ritonavir
drug DRUGBANK Enzalutamide
drug DRUGBANK Nevirapine
drug DRUGBANK Phenytoin
drug DRUGBANK Phenobarbital
drug DRUGBANK Tilmicosin

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *